However, the TCF1+Texprog levels were especially associated with better tumor regression and better overall response in ICB-treated patients.8,10,32 Patients with melanoma who had a higher percentage of TCF1+Texprog respond to ICB therapy for a longer duration. The gene discussed is TCF7; the disease is melanoma.